Welcome
YOU CAN HELP
 
Do you have any ideas or suggestions about information that you would find helpful to see on this website, please contact one of our Project Leaders:

Marie-Hélène Masse
Julie Ménard
Sheila Sprague


Thanks to all Participating Centers and collaborators for engaging in this research program!

Thanks to the CCCTG for endorsing this research project.

LOVIT and LOVIT-COVID Trials


Lessening Organ Dysfunction with VITamin C (LOVIT)

The LOVIT Trial is a multicentre concealed-allocation parallel-group blinded randomized controlled trial to ascertain the effect of high-dose intravenous vitamin C compared to placebo on mortality or persistent organ dysfunction at 28 days in septic intensive care unit patients.
 
The principal investigators of the LOVIT Trial are Dr. François Lamontagne and Dr. Neill Adhikari.

This study is centrally coordinated by the Unité de Recherche Clinique et Épidémiologique (URCE) at the Research Center of the Centre Hospitalier Universitaire de Sherbrooke (CRCHUS), Sherbrooke, QC, Canada. 

This trial was conducted in 35 sites in Canada, New Zealand and France and enrolled 872 patients. The first LOVIT patient was enrolled on November 14, 2018 and the last patient was enrolled on July 19, 2021. We completed the final 6-month follow-up on January 24, 2022. 

We would like to thank the investigators, health care professionals, research and laboratory personnel, study and data coordinators, and the patients and their caregivers who participated in this trial.

The results of the LOVIT trial were presented at the Critical Care Reviews meeting in Belfast on June 15, 2022, and the manuscript was simultaneously published in the New England Journal of Medicine. An updated systematic review was also published in NEJM Evidence (see Relevant Publications).

The study showed that participants in the vitamin C group had a higher risk of death or persistent organ dysfunction at 28 days, compared to participants who received placebo. At day 28, 191 of 429 participants (44.5%) in the vitamin C group had died or had persistent organ dysfunction, as compared with 167 of 434 participants (38.5%) in the placebo group.

Two other studies on the effects of vitamin C in patients with sepsis are in progress: LOVIT India: The Indian Lessening Organ dysfunction with VITamin C in sepsis (PI: Bharath Kumar Tirupakuzhi Vijayaraghavan, India) and LOVIT ARDS: Lessening Organ Dysfunction with VITamin C in septic ARDS (PI: Djillali Annane, France). These are independent trials.

An Individual Patient Data Meta-Analysis (IPDMA) is coming soon.


 

Lessening Organ Dysfunction with VITamin C - COVID-19 (LOVIT-COVID)

The LOVIT-COVID Trial is a multicentre concealed-allocation parallel-group blinded randomized controlled trial to ascertain the effect of high-dose intravenous vitamin C compared to placebo on mortality or persistent organ dysfunction at 28 days in patients with COVID-19, in the hospital either on a medical ward or in the intensive care unit.
 
The principal investigators of the LOVIT-COVID Trial are Dr. François Lamontagne and Dr. Neill Adhikari.

This study is centrally coordinated by the Unité de Recherche Clinique et Épidémiologique (URCE) at the Research Center of the Centre Hospitalier Universitaire de Sherbrooke (CRCHUS), Sherbrooke, QC, Canada. 

This trial is conducted in 15 sites in Canada. Recruitment is actually on pause.





 
CONTACT US if you are interested in joining this trial.